Amgen Stock News

This article was originally published on TipRanks.com Amgen (AMGN) has revealed positive topline results from the Phase 3 DISCREET trial. The post Amgen Reveals Topline Results from Otezla Phase 3 DISCREET Study appeared first on Smarter Analyst .

With the spotlight firmly on Covid variants, its easy to lose sight of what will probably be the most important segment of the biopharma space over the next ten years: oncology. This is where the biggest success stories will be found. Its where the largest revolutions will happen. Its the epicenter of the most important [] The post Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LLY, GILD, MRK) appeared first on Wall Street PR .

Amgen Inc (NASDAQ: AMGN ) announced topline results from the DISCREET trial Phase 3 trial of Otezla (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with placebo, Full story available on Benzinga.com

Key Players covered in the US Biosimilars Market Research Report are Pfizer Inc. (New York, US), Samsung Bioepis (Incheon, South Korea), Celltrion Inc. (Incheon, South Korea), Novartis AG (Basel, Switzerland), Inogen (Goleta, US), Amgen Inc. (California, US), Mylan N.V. (Pennsylvania, US), Coherus BioSciences (California, US), Other Prominent Players Key Players covered in the US Biosimilars Market Research Report are Pfizer Inc. (New York, US), Samsung Bioepis (Incheon, South Korea), Celltrion Inc. (Incheon, South Korea), Novartis AG (Basel, Switzerland), Inogen (Goleta, US), Amgen Inc. (California, US), Mylan N.V. (Pennsylvania, US), Coherus BioSciences (California, US), Other Prominent Players

NEXT Financial Group Inc lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,819 shares of the medical research companys stock after acquiring an additional 132 shares during the []

The global Colorectal Cancer Drugs market size is projected to a CAGR of 4.8% during 2021-2027. The colorectal malignant growth drugs market comprises the offer of colorectal disease drugs. Colorectal disease (CRC) or entrail malignant growth, is the disease influencing

Key Companies Covered in the Regenerative Medicine Market Research Report Are Amgen Inc., Novartis AG, Medtronic Plc., Stryker Corporation, CryoLife, Inc., Integra LifeSciences Corporation, 3M Company, AbbVie Inc., Zimmer Biomet, and other key market players. Key Companies Covered in the Regenerative Medicine Market Research Report Are Amgen Inc., Novartis AG, Medtronic Plc., Stryker Corporation, CryoLife, Inc., Integra LifeSciences Corporation, 3M Company, AbbVie Inc., Zimmer Biomet, and other key market players.

Inflammation is a process by which your body''s white blood cells and the things they make protect you from infection from outside invaders, such as bacteria and viruses. Although it is not proven that inflammation causes cardiovascular disease, inflammation is

THOUSAND OAKS, Calif., Nov. 29, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting the company''s enduring commitment to environmental, social, and governance (ESG) issues.

Bard Financial Services Inc. reduced its position in Amgen Inc. (NASDAQ:AMGN) by 0.1% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 50,270 shares of the medical research companys stock after selling 75 shares during the period. Amgen accounts for approximately 0.9% of Bard Financial Services Inc.s investment portfolio, making the stock its 22nd []

Elite Wealth Management Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 35.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,068 shares of the medical research companys stock after purchasing an additional 800 shares during the quarter. Elite Wealth Management Inc.s []

DNB Asset Management AS lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 6.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 133,820 shares of the medical research companys stock after purchasing an additional 8,396 shares during the quarter. DNB []

Ritholtz Wealth Management cut its stake in Amgen Inc. (NASDAQ:AMGN) by 3.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,786 shares of the medical research companys stock after selling 195 shares during the quarter. Ritholtz Wealth Managements holdings in Amgen were worth $1,230,000 []

Keystone Financial Planning Inc. purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 2,027 shares of the medical research companys stock, valued at approximately $431,000. A number of other institutional investors and hedge funds have also modified their holdings of AMGN. KB Financial Partners LLC acquired []